Evidence map›Paper›PMID 42273248›Full record

ArticleWorld journal of gastrointestinal pharmacology and therapeutics2026

Metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes.

Rishi Chowdhary, Geng-Qing Song, Manjeet Kumar Goyal, Ashita Rukmini Vuthaluru, Kirti Arora, Rahul Chowdhary, Megh Patel, Akash Batta, Thai-Hau Koo, Venkata Sunkesula and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rishi ChowdharyDepartment of Medicine, MetroHealth Medical Center, Cleveland, OH 44109, United States.
Geng-Qing SongDepartment of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH 44109, United States.
Manjeet Kumar GoyalDepartment of Internal Medicine, Cleveland Clinic Akron General Hospital, Akron, OH 44308, United States.
Ashita Rukmini VuthaluruDepartment of Anesthesiology, All India Institute of Medical Sciences, New Delhi 110029, Delhi, India.
Kirti AroraDepartment of Internal Medicine, Cleveland Clinic Akron General Hospital, Akron, OH 44308, United States.
Rahul ChowdharyDepartment of Internal Medicine, Cleveland Clinic Main Campus, Cleveland, OH 44106, United States.
Megh PatelDepartment of Medicine, B. J. Medical College, Ahmedabad 380016, Gujarāt, India.
Akash BattaDepartment of Cardiology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India.
Thai-Hau KooGastrointestinal Function and Motility Unit, Hospital Pakar Universiti Sains Malaysia, School of Medical Sciences, Kubang Kerian 16150, Kelantan, Malaysia.
Venkata SunkesulaDepartment of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH 44109, United States.
Rohit GoyalDepartment of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, United States.
Omesh GoyalDepartment of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and often coexists with obstructive sleep apnea (OSA). Emerging evidence suggests that OSA may independently accelerate liver injury in MASLD. Despite this the epidemiology and clinical significance of OSA within the population with MASLD remain incompletely understood.

aimTo estimate the prevalence of OSA among MASLD and determine the impact of OSA on hepatic complications.

methodsThis was a large, multicenter, population-based retrospective cohort study conducted using the TriNetX Global Health Research Network from 2010 to 2024. We identified adults with MASLD with International Classification of Diseases, Tenth Revision codes and propensity score matched (PSM) them 1:1 with adults without MASLD. Patients with any record of prior liver disease other than MASLD or OSA (G47.3x) before the MASLD index date were excluded from the study.

resultsAfter PSM there were 364283 pairs analyzed with balanced covariates. From 2010-2024 OSA incidence and prevalence in MASLD increased more than 400-fold (

conclusionMASLD was associated with a significantly higher risk of OSA, and coexisting OSA substantially amplified long-term hepatic complications. In addition, MASLD was associated with an earlier onset of OSA, highlighting the need for integrated hepatology-sleep medicine approaches and early identification and treatment of OSA in MASLD cohort may prevent the development of complications such as hepatic fibrosis and cirrhosis.

Indexed as

CirrhosisIntermittent hypoxiaLiver fibrosisMetabolic dysfunction-associated steatotic liver diseaseMetabolic syndromeObstructive sleep apneaSleep-disordered breathingTriNetX

Identifiers

PMID42273248
PMCPMC13248218

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.